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Fusarium is regarded as one of the most important mycotoxigenic fungi genera. It is 
known to produce several classes of mycotoxins of which the trichothecenes are the most 
important based on occurrence. From this class of mycotoxins, type A trichothecenes are the 
more toxic subclass. T-2 toxin (T-2)is the most acute toxic mycotoxin of the type A 
trichothecenes. It is  commonly found in cereals and several European surveys have reported 
T-2 incidences over 80% for certain cereals and maximum concentrations up to 2,406 µg/kg 
have been observed in naturally contaminated oats [1-4]. 
Poultry is considered to have a high exposure to T-2 as their diet is mainly cereal based. 
Toxic effects in poultry include inhibition of protein, DNA and RNA synthesis, 
immunomodulation, gastro-intestinal cell lesions, organs and neural disturbances [5]. At 
subclinical levels decreased performance parameters can be observed [6].  
For broiler chickens, first adverse effects like mucosal damage in the oral cavity occur at 
a dose of 40 µg/kg body weight (bw) per day. For laying hens, a reduction of the egg 
production and hatchability were observed at doses of 120 µg/kg bw per day [6]. Based on 
these data the European Union has issued indicative levels for the sum of T-2 and HT-2 toxin 
(HT-2) in food and feed commodities, from above which investigations should be performed, 
certainly in case of repetitive findings [7, 8]. For poultry compound feed, the indicative level 
is set at 250 µg T-2 + HT-2/kg feed.  
The indicative levels suggested by legislative authorities only take into account free 
mycotoxins, such as T-2 and HT-2. However, based on recent research this appears to be an 
incomplete approach, as additionally to free mycotoxins, food and feed is often co-
contaminated with modified mycotoxins. For T-2, in planta glycosylation of the 3-hydroxyl 
group to T-2 toxin-β-glucoside (T2-G) could be an important contributor to modified forms 
based on recent studies. The occurrence of T2-G in naturally infected wheat and oats has 
been described by Lattanzio et al. (2011). Based on High-Resolution Mass Spectrometry 
(HRMS) peak area ratios between glucoside derivatives and free T2 and HT-2 in naturally 
contaminated wheat and oats samples,  amounts of glycosylated T-2 and HT-2  as high as 
27% of their deglycosylated counterparts were demonstrated [9]. Furthermore, Busman et 
al. and Lattanzio et al. observed that glycosylation is not only part of a detoxification 
strategy by plants, but can also be a relevant route of fungal metabolism [10, 11]. 
The European Food Safety Authority (EFSA) recently published a scientific opinion on 
modified mycotoxins. In this opinion the relative contribution of modified forms of T-2 to the 
occurrence of T-2 was calculated to be 10%. The risk of this T2-G contribution was assessed 
for humans and several animal species (pigs, ruminants, horses, poultry and dogs) where 
possible. The combined risk of T-2, HT-2 and their modified forms was found not to be of 
concern, except for the highest upperbound exposure for toddlers, with levels slightly 
exceeding the TDI. Furthermore, the risk assessment assumed that all modified forms have 
the same toxicity as their parent compounds, and this due to the lack of information on 
bioavailability and toxicity of these modified forms [1]. However, as shown by several 
studies, modified mycotoxins may have a significantly altered inert toxicity and oral 
bioavailability; in addition they may be subject to in vivo hydrolysis as well [12-14]. These 
knowledge gaps pose an additional uncertainty on the derived conclusions of this scientific 
opinion. 
Presently, no toxicokinetic data is available for T2-G in humans nor animals. 
Determination of the absolute oral bioavailability, in vivo hydrolysis and toxicokinetic 
characteristics could significantly contribute to an accurate risk assessment by legislative 
authorities on modified mycotoxins such as T2-G. 
 
2. Experimental 
2.1 Compounds, standards and solutions 
T-2, HT-2 and T-2 triol were purchased from Fermentek (Jerusalem, Israel). T2-G was 
synthesized by the United States Department of Agriculture (USDA) as described [15]. All 
compounds were dissolved in ethanol yielding a stock solution of 10 mg/mL. The internal 
standard (IS), 25 µg/mL 13C24-T-2 toxin solution in acetonitrile, was purchased from Sigma 
Aldrich (Bornem, Belgium). All stock solutions were stored at ≤−15 °C. Individual working 
standard solutions of 100 µg/mL were prepared by diluting the above stock solutions with 
HPLC-grade acetonitrile. All standard solutions were stored at ≤−15 °C. Standard mixture 
working solutions (containing T-2, HT-2, T-2 triol and T2-G) of 5,000, 500, 50 and 5 ng/mL 
were prepared by mixing and diluting the individual working standard solutions in HPLC-
grade acetonitrile and were kept at 2-8 °C. Acetonitrile solutions of T-2 and HT-2 have been 
reported stable for 24 months at 25 °C [16]. For T-2 triol no published stability data is 
available. However, suppliers claim a stock solution shelf-life of at least one month at ≤−15 
°C. Regarding synthesised T2-G, no data is published on storage and stability. During the 
study no degradation of the T2-G solutions into T-2, HT-2 and T-2 triol could be detected by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. 
 
2.2 Instrumentation, materials & reagents 
Separation of analytes was achieved on an Acquity UPLC® BEH C18 column (150 x 2.1 
mm i.d., 1.7 μm) with an Acquity UPLC® BEH C18 column VanGuard pre-column (5 x 2.1 mm 
i.d., 1.7 µm). An Acquity UPLC system coupled to a Xevo® TQ-S mass spectrometer was used, 
operating in positive electrospray ionization (ESI+) mode, all from Waters (Zellik, Belgium). 
Microfilters Durapore PVDF (0.22 µm) were obtained from Millipore (Overijse, Belgium). 
Water, methanol, acetic acid and ammonium acetate (all UHPLC grade) were purchased 
from Biosolve (Valkenswaard, The Netherlands). Acetonitrile (HPLC grade) was obtained 
from VWR (Leuven, Belgium). 
  
2.3 Plasma sample preparation 
 Blank plasma samples. Heparinized blood from 12 h fasted broiler chickens 
(Ross 308, Institute for Agricultural and Fisheries Research (ILVO) animal unit, Merelbeke, 
Belgium) was centrifuged (2,851 x g, 10 min, 4 °C) to obtain blank plasma. This plasma was 
pooled, homogenized and stored in 15 mL aliquots at ≤ – 15 °C until the moment of use as 
matrix-matched calibrators and quality control samples. 
Calibrator and quality control samples.  To 200 µL of blank plasma, 20 µL of a 100 
ng/mL IS working solution and appropriate volumes of the standard mixture working 
solutions (5,000, 500, 50 and 5 ng/mL) were added to obtain calibrator samples with 
mycotoxin concentrations of 0.1, 1, 5, 10, 50, 100, 500 and 1,000 ng/mL. Acetonitrile was 
added up to a volume of 1.0 mL to precipitate plasma proteins. After vortex mixing and 
centrifugation (8,517 x g, 10 min, 4 °C), the supernatant was isolated and evaporated to 
dryness under nitrogen at 40 °C. The sample was then redissolved in 200 µL of a UHPLC-
grade water/methanol mixture (85/15; v/v), filtered (0.22 µm) and analyzed by LC-MS/MS. 
Incurred samples. To 200 µL of plasma, 20 µL of a 100 ng/mL IS working solution 
were added and the samples were subjected to the same sample preparation procedure as 
the calibrator samples. 
  
2.4 LC-MS/MS analysis 
 Analytes were eluted at a flow rate of 300 µL/min with mobile phase A consisting of 
water, methanol and acetic acid (97/2/1; v/v/v) + 5 mM aqueous ammonium acetate, and 
mobile phase B consisting of water, methanol and acetic acid (2/97/1; v/v/v) + 5 mM 
ammonium acetate. A gradient elution program was applied: 0-1 min (70% A, 30% B), 1.0-1.1 
min (linear gradient to 50% B), 1.1-5.0 min (50%  A, 50% B), 5.0-5.1 min (linear gradient to 
95% B), 5.1-8.0 min (5% A, 95% B), 8.0-8.1 min (linear gradient 30% B), 8.1-10.0 min (70% A, 
30% B). Column and autosampler temperatures were set to respectively 40 and 8 °C, 
injection volume (partial loop) was fixed at 10 µL. 
 The mass spectrometer was operated in the multiple reaction monitoring (MRM) 
mode with two ion transitions for each target analyte. Instrumental and compound specific 
parameters were optimized by the direct infusion of 10 ng/mL standard solutions in a 50/50 
(v/v) mixture of mobile phase A and B at a flow rate of 50 µL/min. Capillary voltage was set 
at 2.5 kV, cone at 15 V, cone gas flow 150 L/h, desolvation temperature at 600 °C, 
desolvation gas flow at 1000 L/h and collision gas flow at 150 µL/min. All compounds were 
detected in ESI+. Compound specific instrumental parameters, together with precursor and 
product ions used for quantification and qualification, are given in Table 1.  
 
2.5 Validation 
Validation was performed on spiked blank plasma samples. As validation guidelines 
recommendations by the European Community [17, 18] and the Veterinary International 
Conference on Harmonisation (VICH) [19] were utilized.  
Linearity of the response of the compounds was assessed by means of three matrix-
matched calibration curves consisting of at least seven calibration points in the range of 0.1-
100 ng/mL for HT-2, T-2 triol and T2-G and in the range of 0.1-1,000 ng/mL for T-2. Utilised 
criteria and corresponding acceptability ranges were correlation coefficients (r) ≥0.99 and 
goodness-of-fit coefficients (gof) ≤20%. 
Within-day accuracy & precision were determined by analyzing six samples at a low 
concentration level (limit of quantitation or LOQ of the analytes) and at a high concentration 
level (range maximum). Values for the relative standard deviation (RSD) should not exceed 
2/3 of the RSDmax, calculated according to the Horwitz equation [20]. The acceptance criteria 
for accuracy were: −50% to +20%, −30% to +10% and −20% to +10% for concentrations ≤ 0.1 
ng/mL, between 1 and 10 ng/mL, and ≥10 ng/mL, respectively.  
Between-day accuracy & precision were assessed by analyzing the LOQ and range 
maximum in threefold on three consecutive days (n=3x3). The acceptance criteria for 
accuracy were identical to the values given above and RSD values should not exceed the 
RSDmax [20]. 
The LOQ was calculated as the lowest concentration for which the method had 
acceptable results with regards to accuracy and precision. It was determined by spiking 6 
plasma samples at 0.1, 0.2, 0.5, 1 or 2 ng/mL. The LOQ was also established as the lowest 
point of the calibration curve. The limit of detection (LOD) was calculated using the signal-to-
noise (S/N) ratio of the samples spiked at the LOQ level (n=6) corresponding to the 
concentration with a S/N ratio of 3.  
Carry-over was evaluated by analysing a mixture of mobile phase A and B (50/50; v/v) 
directly after the highest calibrator. 
The specificity, the capability of the method to distinguish signals of the analytes 
from other substances or interferences, was determined on six blank plasma samples. For an 
acceptable specificity the S/N ratio of possible interfering peaks with similar retention times 
in these samples could not exceed the S/N ratio of the analyte(s)’ LOD. 
Recovery and matrix effects. Two types of matrix-matched calibration curves were 
prepared, one by spiking the blank calibrator samples before and one after extraction. A 
third calibration curve was prepared in standard solution. All curves consisted of five 
calibration points in the range of 1-100 ng/mL. The slopes of these calibration curves were 
compared to calculate the apparent recovery (RA = 100 × slope spiked before 
extraction/slope standard solution), the matrix effect denoted as signal 
suppression/enhancement (SSE = 100 × slope spiked after extraction/slope standard 
solution) and the recovery of the extraction step (RE = 100 × slope spiked before 
extraction/slope spiked after extraction). Regarding SSE, values ≤ 100% indicate ion 
suppression due to matrix effect, values ≥ 100% are caused by ion enhancement [21]. 
 
2.6 Animal trial 
Six broilers (Ross 308, mixed sex, 18 days of age) were housed at the Faculty of 
Veterinary Medicine of Ghent University. Water and feed were present ad libitum. The 
animals were allowed to acclimatize for 1 week in a climate-controlled stable with 
temperatures between 18 and 25 °C, a relative humidity between 40 and 80% and a 18 h/6 h 
light/dark cycle. Three broilers were given a single T2-G intravenous injection (IV) and three 
broilers a single per os bolus (PO, by means of gavage directly into the crop). After a one day 
washout period, the animals were administered T-2 by IV or PO in a two-way cross-over 
design with a one day washout period (Figure 1). Twelve hours before administration of T-2 
or T2-G the animals were fasted. In order to obtain detectable plasma concentrations after 
PO administration it was opted to use 1 mg/kg T2-G and an equimolar dose of T-2, 0.74 
mg/kg. Mycotoxin solutions (10 mg/mL in ethanol) were diluted with saline (0.9% NaCl, 
VWR, Leuven, Belgium) to an administration volume of one mL. Before the administration of 
the toxins (0) and 2, 5, 10, 15, 20, 30, 45, 60, 90 and 120 min afterwards, blood (0.5 – 1 mL) 
was collected. The animal trial was approved by the ethical committee of the Faculty of 
Veterinary Medicine and the Faculty of Bioscience Engineering (EC2013/139). 
 
2.7 Toxicokinetic modeling and statistical analysis 
Toxicokinetic analysis was performed using WinNonlin Professional version 5.2.1. 
(Pharsight, St-Louis, MO, USA). Plasma concentrations below the LOQ were not taken into 
account. For the analysis of T-2 and T2-G, a two-compartmental model (central 
compartment (Vc) and peripheral compartment (Vp)) with first-order elimination was 
applied.  
The following primary and secondary toxicokinetic parameters were calculated from the 
IV data: total body clearance (CL), central volume of distribution (Vc), peripheral volume of 
distribution (Vp), disposition rate constant (β) and disposition half-life (t1/2β). Absorption 
rate constant (ka), maximal plasma concentration (Cmax) and time to maximal plasma 
concentration (tmax) were calculated based on the PO data. A 1/ŷ weighing was applied for all 
calculations. 
F, determined for T-2 and T2-G, indicates the absolute oral bioavailability, i.e. the 




FRAC, determined for T-2 and T2-G, is the absorbed fraction of the dose in either form, 





Presystemic hydrolysis (Pres. Hydr.) of T2-G is the percentage of the total dose that is 
hydrolysed presystemically to T-2 and absorbed as T-2 (%), calculated by correcting for 




Statistical analysis of FRAC, F, Cmax and tmax after T2-G administration compared to after 
T-2 administration consisted of one-way ANOVA with post-hoc Scheffé tests (p < 0.05) (SPSS 
20.0, IBM, Chicago, IL). All variables were log transformed in order to fulfill the equality of 




3. Results and discussion 
The results for linearity, r and gof, sensitivity, LOD and LOQ, are given in Table 2. The 
results for linearity were all in accordance with the acceptance criteria, with r ≥ 0.99 and gof 
≤ 20%. LOD varied from 0.01 (T-2 triol), 0.02 (T-2 and T2-G) to 0.04 (HT-2) ng/mL. LOQ was 
0.1 ng/mL for all mycotoxins. Table 3 displays the results for accuracy (%) and precision 
(RSD, %). All results fell within the specified acceptability ranges.  
The method was specific as no interfering peaks were detected in the 
chromatographic elution zone of the analytes with S/N values ≥ 3 (results not shown). 
Furthermore, carry-over was evaluated (results not shown). For none of the compounds 
signals were detected that could interfere with the response/area of the analytes at their 
given retention time.  
In preliminary studies administered doses calculated based on EU maximum guidance 
values in feed could not be detected in plasma of broilers after PO administration [22]. 
Consequently, this set up did not allow to calculate the absolute oral bioavailability of T-2. A 
recent study by Sun et al. orally dosed broilers at 2.0 mg T-2 per kg bw, resulting in 
detectable plasma profiles [23]. Consequently, the initially planned dose was increased to 
use 1 mg T2-G/kg bw and an equimolar doses of T-2, 0.74 mg/kg bw. 
Plasma concentration-time profiles for PO and IV administration of T-2 (n=6) and T2-
G (n=3) to broiler chickens are presented in Figure 2. Each profile is represented as the mean 
± standard deviation (SD).  
During the animal trial none of the broiler chickens showed any adverse effects after 
acute IV or PO administration of T-2G. Within 24 h after the T-2 cross-over one broiler died. 
However, this could not be directly related to the administration of the mycotoxin. The other 
broilers showed no clinical symptoms of the T-2 IV and PO administration. 
A first observation from the plasma concentration-time profiles is that after PO and 
IV administration of T-2 and T2-G to broilers no T-2 triol and only traces of HT-2 were 
detected in plasma. In contrast, Sun et al. detected high amounts of HT-2 and T-2 triol after 
IV administration of T-2 (0.5 mg/kg bw), as well as high concentrations of T-2 triol after PO T-
2 administration (2 mg/kg) [23].  
The calculated F of T-2 in chickens is 2.17±1.80%. Sun et al. calculated a notably 
higher F of T-2, i.e. 17.1% [23]. Osselaere et al. administered T-2 IV and PO (15 µg/kg bw) to 
chickens and no plasma levels above the LOQ could be observed for T-2 and its metabolite 
HT-2. Consequently, no determination of F was possible. Given the LOQ of 2.5 ng/mL of the 
latter method, it does indicate a likely low F, in correspondence with the findings of this 
study. 
 The values for CL (191 mL/min/kg), β (0.0346/min), t1/2β (21.4 min) and Vss (sum of 
Vc and Vp; 3240 mL/kg) correspond well with the values obtained by Sun et al., i.e. 120 
mL/min/kg, 0.04/min, 17.3 min and 3170 mL/kg, respectively [23]. In contrast, the values for 
these toxicokinetics parameters described by Osselaere et al. differ significantly, this 
discrepancy is probably caused by the application of a non-compartmental model [22]. 
For T2-G a FRAC and F of 10.4±8.7% and 10.1±8.5% were determined, respectively. 
This slight difference is caused by a partial presystemic hydrolysis, 3.85±1.31%, of T2-G to T-
2. The FRAC of T2-G is five times higher than that of T-2. Mean T2-G volumes of distribution, 
CL and Cmax values were significantly larger than those observed for T-2. Mean values for β 
(0.0285/min) and t1/2β (24.3 min) of T2-G do not significantly differ from those obtained for 
T-2. 
These differences in toxicokinetics parameters between T-2 and T2-G, specifically the 
five times higher FRAC for T2-G, clearly indicate the flaw in assuming equal toxicity of 
modified and parent compounds in risk assessment [1]. For every amount of T2-G in feed, 
compared to T-2, the systemic exposure to the glucoside conjugate will be five times higher. 
Consequently, the contribution in feed, estimated at 10% would result in an in vivo 
contribution of 50%. This clearly indicates the flaw in assuming equal toxicity of modified 
and parent compounds in risk assessment. 
Assuming equal intrinsic toxicity is similarly flawed. Although no T2-G toxicity data is 
available, a clearly decreased toxicity has been demonstrated for deoxynivalenol-3-glucoside 
(DON3G) compared to DON [21,24-26]. Given the high degree of structural similarity 
between DON and T-2, a similar decrease in toxicity may reasonably be expected for T2-G. 
Furthermore, as seen with DON3G, T2-G was not hydrolysed in broiler chickens to its 
respective free mycotoxin in a significant extent. Consequently, although a relatively higher 
oral bioavailability and absorbed fraction were observed, further research is needed as the 
contribution of these modified forms to the overall toxicity of these mycotoxins may be 
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Figure 1. Two-way cross-over design (IV and PO) for T-2 (blue) in six broilers with a one day 






Figure 2. Plasma concentration-time profiles of T-2 toxin (T-2) and T-2-glucoside (T2-G) after 
oral (PO) and intravenous (IV) administration of T-2 (0.76 mg/kg bodyweight, n=6) and T2-G 




Table 1. Compound specific MRM ion transitions and MS-parameters; Rt= retention time; IS= internal standard; 







Rt (min) Collision 
Energy 
T-2 [M+NH4]+ 484.1 245.4a 
5.7 
12 
   305.4 12 
HT-2 [M+Na]+ 447.2 285.1a 
4.2 
20 
   345.1 18 
T-2 triol [M+Na]+ 405.0 124.9a 
3.3 
15 
   303.0 15 
T2-G [M+Na]+ 650.9 326.9a 
4.5 
40 
   406.9 40 
13C24-T-2 (IS) [M+NH4]+ 508.2 198.0a 
5.7 
22 




Table 2. Validation results for linearity (r & gof, minimum 7 concentration points), sensitivity (LOD & LOQ; n=6), 


















T-2 0.1-1000 0.9999 6.52% 0.02 0.1 96.6 77.8 80.5 
HT-2 0.1-100 0.9981 17.33% 0.04 0.1 31.6 81.3 257 
T-2 triol 0.1-100 0.9984 10.79% 0.01 0.1 19.7 55.4 282 
T2-G 0.1-100 0.9910 13.36% 0.02 0.1 41.8 76.7 183 
 
 
Table 3. Validation results for within-day precision (n=6) and between-day precision (n=3x3) with 
corresponding accuracy at low (LOQ) and high (Linearity range maximum) concentration level 
 Within-day (n=6) Between-day (n=3x3) 
 Accuracy (%) Precision (RSD, %) Accuracy (%) Precision (RSD, %) 
 LOQ Range max LOQ Range max LOQ Range max LOQ Range max 
T-2 8.3 -0.4 18.8 2.6 11.1 -0.5 7.0 1.4 
HT-2 -42.0 -6.0 18.9 2.7 -40.0 -5.1 18.6 2.7 
T-2 triol -10.0 -4.5 17.6 2.1 -1.1 -3.3 19.2 2.8 
T2-G -9.-9 -3.8 19.6 2.3 -31.1 -3.2 30.2 2.5 
 
 
Table 4. Toxicokinetic parameters, absolute oral bioavailability (%) and presystemic hydrolysis (%) of T-2 (n=6) 
and T2-G (n=3) after IV to broiler chickens.  
 T-2 T2-G 
β (1/min) 0.0346±0.0088 0.0285±0.0017 
t1/2β (min) 21.4±6.6 24.3±1.4 
CL (mL/min/kg) 191±42 377±85* 
Vc (mL/kg) 1173±387 2705±1281* 
Vp (mL/kg) 2067±744 4568±1838* 
FRAC (%) 2.17±1.80 10.4±8.7* 
Pres.Hydr. (%) - 3.49±1.19* 
F (%) 2.17±1.80 10.1±8.5* 
Cmax (ng/mL) 5.55±7.49 33.9±27.0* 
tmax (min) 8.14±4.38 4.67±4.62 
Values are presented as mean ± SD. ke=elimination rate constant (1/min); t1/2el=elimination half-live (min); CL=clearance (mL/min/kg); 
Vc=central volume of distribution (mL/kg); Vp=peripheral volume of distribution (mL/kg); FRAC=absorbed fraction (%); 
Pres.Hydr.=percentage of the total dose that is hydrolysed presystemically (%); F=absolute oral bioavailability (%); Cmax=maximum plasma 
concentration (ng/mL); tmax= time to maximum plasma concentration (min); Statistical analysis was performed by means of ANOVA,* 
statistically significant difference (p<0.05)  
 
 
 
